This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
by Zacks Equity Research
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
Merck (MRK) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.98, moving -0.25% from the previous trading session.
5 Finest PEG Stocks for GARP Investors
by Urmimala Biswas
Here are five picks out of 45 top-ranked stocks with discounted PEG.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
by Zacks Equity Research
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
Cocrystal Pharma (COCP) Completes Research Obligations With Merck
by Zacks Equity Research
Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.
Why Merck (MRK) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
by Zacks Equity Research
Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
by Zacks Equity Research
AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.
Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids
by Zacks Equity Research
FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Merck (MRK) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $82.17 in the latest trading session, marking a -0.21% move from the prior day.
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
by Zacks Equity Research
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.
Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence
by Zacks Equity Research
Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $83.03, marking a -1.18% move from the previous day.
Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola (KO), Merck (MRK), and Royal Dutch Shell (RDS.A).
Pfizer (PFE) Begins Dosing in DMD Study With Gene Therapy
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the phase III CIFFREO study, evaluating its investigational gene therapy, PF-06939926, for treating boys with DMD.
Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates
by Kinjel Shah
AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.
Dow Jones Jumps 600 Points: Bet on 4 Momentum Stocks to Win Big
by Radhika Pujara
Here we discuss four momentum-focused top-ranked Dow Jones stocks -- JPM, GS, PG and MRK -- that are well poised to flourish in 2021 on strong fundamentals.
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
by Zacks Equity Research
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.